Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bill Gates Meets With Sinovac Scientists In Beijing: Will They Be Integrated Into Gates Foundation's Global Immunization Drives?

This article was originally published in PharmAsia News

Executive Summary

BEIJING - During a whirlwind tour of China, Microsoft founder Bill Gates met with scientists at China's leading vaccine developer, Sinovac Biotech, as the Gates Foundation ramps up a project to supply vaccines to kids in need across the planet

You may also be interested in...



Leading Chinese Vaccine Developer Sinovac Conducts Technical Exchanges With Gates Foundation On Rotavirus Vaccine

BEIJING - China's leading vaccine developer, Sinovac Biotech, is applying for Chinese regulatory approval to launch clinical trials for two new pneumococcal polysaccharides vaccines

Leading Chinese Vaccine Developer Sinovac Conducts Technical Exchanges With Gates Foundation On Rotavirus Vaccine

BEIJING - China's leading vaccine developer, Sinovac Biotech, is applying for Chinese regulatory approval to launch clinical trials for two new pneumococcal polysaccharides vaccines

China's Leading Vaccine Developer Sees Sales Slashed Due To Popular Backlash Against Series Of Scandals

BEIJING - Pummeled by a de facto nationwide public boycott of domestically produced inoculations following a series of faulty vaccine releases by other firms that have in some cases led to fatalities, China's leading vaccine maker, Sinovac Biotech, reported sales revenues for 2010 that were just half of original projections

Related Content

UsernamePublicRestriction

Register

SC073457

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel